Connect with us

Cute Animals

Promising New Malaria Drug Matches Current Treatments

Published

on

Quick Smiles:

  • New malaria drug KLU156 is as effective as existing treatments
  • Drug cured 99.2% of cases in a large African clinical trial
  • Could help prevent drug resistance and interrupt malaria transmission

Encouraging developments come as a new antimalarial medication, KLU156, has proven just as effective as current treatments in a major drug trial. Over 1,600 participants across 12 African countries experienced a 99.2% cure rate, slightly higher than the 96.7% seen with existing therapies.

KLU156 combines ganaplacide, discovered through advanced computing analysis by Novartis, with lumefantrine, a familiar partner in traditional therapies. The new drug not only kills malaria parasites quickly but may also block the reproductive stage that allows transmission by mosquitoes.

“Having a new compound that is not artemisinin-based, and that is that effective and safe, is really music to my ears,” said Abdoulaye Djimdé, a malaria researcher involved in the study.

The success offers hope as resistance to current therapies becomes an increasing challenge. Researchers are working on improving the taste to reduce side effects so that more patients can complete their treatments.

This exciting progress could offer health professionals a powerful new tool against malaria, providing fresh hope to millions impacted by the disease each year.

Stay tuned to more promising medical breakthroughs that brighten our world and inspire hope in global health!

Source

Advertisement
Advertisement
1 Comment

1 Comment

  1. Alwine Herriot

    November 18, 2025 at 11:31 am

    I was tired 0f living paycheck to paycheck and knew s0mething had to change. After finding an 0nline 0pp0rtunity, I started earning $16,800 a m0nth, and it’s been the m0st rewarding experience 0f my life. If you’re ready t0 take charge of your future, this is y0ur moment..

    ➤ The site is menti0ned Teb on my pr0file name”

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending